Accepted Article This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/dme.13393 This article is protected by copyright. All rights reserved. DR SUBIR RAY (Orcid ID : 0000-0002-2362-1139) Article type : Letter Title: Diabetic Medicine Created by: Maria Hale Email proofs to: subirray@gmail.com Copyright: Diabetes UK Article no.: DME-2017-00178 Article type: Letter Short title/Authors running head: Letter  S. Ray and J. J. Mukherjee Combination therapy with multiple oral hypoglycaemic agents together with short-term basal insulin in new-onset Type 2 diabetes mellitus with marked hyperglycaemia Type 2 diabetes mellitus is characterized by the relentless loss of β-cell function, which is partly attributable to glucotoxicity and lipotoxicity. Prolonged exposure to excess glucose and oxidative stress leads to β-cell destruction [1,2]. Evidence suggests that early intensive intervention to achieve normoglycaemia can preserve β-cell function, probably by correcting glucotoxicity and lipotoxicity [3]. The management of people with new-onset Type 2 diabetes with marked hyperglycaemia remains unclear. The American Diabetes Association recommends using dual therapy in people with new-onset Type 2 diabetes when HbA 1c is ≥ 75 mmol/mol (9%), and injectable